- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06965504
Initiering og titrering av retningslinjer rettet medisinsk terapi i hjertesvikt Kardiogent sjokk med Impella 5.5 for hjertegjenoppretting (integrere) (INTeGRATE)
Initiering og titrering av retningslinjer rettet medisinsk terapi i hjertesvikt Kardiogent sjokk med Impella 5.5 for hjertegjenoppretting: Integrer
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, single arm, multi-center, post-market, on-label study. For patients presenting with cardiogenic shock in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis (also known as decompensated heart failure complicated with cardiogenic shock, commonly referred to as heart failure-related cardiogenic shock, HF-CS, including both acute-on-chronic and de novo presentations) as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP), an intentional device-supported strategy with Impella 5.5™ for optimization of guideline-directed medical therapy (GDMT) combined with best practices improves outcomes over standard of care.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Roberta Chapman, MD, FACC, FACP, FHFSA
- Telefonnummer: +1 978-882-8421
- E-post: rchapm11@its.jnj.com
Studer Kontakt Backup
- Navn: Stacie Hallaway
- Telefonnummer: 839-216-3087
- E-post: shallawa@its.jnj.com
Studiesteder
-
-
California
-
Sacramento, California, Forente stater, 95816
- Har ikke rekruttert ennå
- Sutter Medical Center Sacramento
-
Hovedetterforsker:
- Michael Gibson, MD
-
Ta kontakt med:
- Bonnie Chan
- Telefonnummer: 415-463-0379
- E-post: bonnie.chan2@sutterhealth.org
-
San Francisco, California, Forente stater, 94110
- Har ikke rekruttert ennå
- California Pacific Medical Center
-
Ta kontakt med:
- Bonnie Chan
- Telefonnummer: 415-463-0379
- E-post: bonnie.chan2@sutterhealth.org
-
Hovedetterforsker:
- Jared Herr, MD
-
Hovedetterforsker:
- Michael Pham, M.D., FACC, MPH
-
-
Florida
-
Naples, Florida, Forente stater, 34102
- Har ikke rekruttert ennå
- NCH Rooney Heart Institute
-
Ta kontakt med:
- Kathy Byrd
- Telefonnummer: 239-624-8113
- E-post: kathy.byrd@nchmd.org
-
Hovedetterforsker:
- Viviana Navas, MD
-
Tampa, Florida, Forente stater, 33606
- Rekruttering
- Tampa General Hospital
-
Ta kontakt med:
- Courtney Nicholas, BS RN, CCRP, CVRN-BC
- Telefonnummer: 813-844-4914
- E-post: courtneynicholas@tgh.org
-
Hovedetterforsker:
- Debbie Rinde-Hoffman, MD, FACC, FACP, FHFSA
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46260
- Har ikke rekruttert ennå
- Ascension St. Vincent
-
Ta kontakt med:
- Jennifer Brown
- Telefonnummer: 317-338-6439
- E-post: Jennifer.Brown4@ascension.org
-
Hovedetterforsker:
- Sunit-Preet Chaudhry, MD, FACC
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 555407
- Rekruttering
- Abbott Northwestern
-
Ta kontakt med:
- Juilanne Feola
- Telefonnummer: 612-863-6066
- E-post: julianne.feola@allina.com
-
Hovedetterforsker:
- Kasia Hryniewicz, MD
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Har ikke rekruttert ennå
- Barnes Jewish
-
Ta kontakt med:
- Jean Flanagan
- Telefonnummer: 314-454-7451
- E-post: jflanaga@wustl.edu
-
Hovedetterforsker:
- Justin Vader, MD, MPHS
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Har ikke rekruttert ennå
- Hackensack University Medical Center
-
Hovedetterforsker:
- Kanika Mody, MD
-
Ta kontakt med:
- Manuel Castillo
- Telefonnummer: 551-996-2136
- E-post: manuel.castillo@hmhn.org
-
New Brunswick, New Jersey, Forente stater, 08901
- Rekruttering
- Rutgers-Robert Wood Johnson Medical School
-
Ta kontakt med:
- Manisha Bajpai, MD
- Telefonnummer: 732-258-3649
- E-post: bajpaima@rwjms.rutgers.edu
-
Hovedetterforsker:
- Maya Guglin, MD, PhD
-
-
New York
-
New York, New York, Forente stater, 10032
- Har ikke rekruttert ennå
- New York Presbyterian - Columbia
-
Hovedetterforsker:
- Adil Yunis, MD
-
Ta kontakt med:
- Jessica Idumonyi
- Telefonnummer: (212) 305-1429
- E-post: joi2102@cumc.columbia.edu
-
Valhalla, New York, Forente stater, 10595
- Har ikke rekruttert ennå
- Westchester Medical Center
-
Hovedetterforsker:
- Alan Gass, MD
-
Ta kontakt med:
- Rajkumari Bhardwa
- Telefonnummer: 914-493-5599
- E-post: Rajkumari.Bhardwaj@wmchealth.org
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Har ikke rekruttert ennå
- Atrium Health- Sanger Heart and Vascular Institute
-
Ta kontakt med:
- Haley Bonilla
- Telefonnummer: 704-468-3193
- E-post: haley.bonilla@atriumhealth.org
-
Hovedetterforsker:
- Priyesh Patel, M.D.
-
Durham, North Carolina, Forente stater, 27710
- Har ikke rekruttert ennå
- Duke University
-
Ta kontakt med:
- Elyse Wilson
- Telefonnummer: (919) 681-8879
- E-post: elyse.wilson@duke.edu
-
Hovedetterforsker:
- Adam DeVore, MD, MHS, FHFSA, FAHA, FACC
-
Winston-Salem, North Carolina, Forente stater, 27157
- Har ikke rekruttert ennå
- Wake Forest Baptist Medical Center
-
Ta kontakt med:
- Karen Blinson Research Coordinator
- Telefonnummer: 336-716-5706
- E-post: karen.blinson@advocatehealth.org
-
Hovedetterforsker:
- Olivia Gilbert, MD
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74136
- Har ikke rekruttert ennå
- Saint Francis Hospital - Tulsa
-
Hovedetterforsker:
- Jaime Hernandez-Montfort, MD
-
Ta kontakt med:
- Jennifer Nangle
- Telefonnummer: 918-502-1603
- E-post: jnangle@saintfrancis.com
-
-
Oregon
-
Portland, Oregon, Forente stater, 97225
- Har ikke rekruttert ennå
- Providence St. Vincent Medical Center
-
Ta kontakt med:
- Sarah Jackson
- Telefonnummer: 503-216-7370
- E-post: sarah.jackson3@providence.org
-
Hovedetterforsker:
- Vidang Nguyen, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Har ikke rekruttert ennå
- University of Pennsylvania Health System
-
Ta kontakt med:
- Alyson Brown
- Telefonnummer: 215-662-2128
- E-post: alyson.brown@pennmedicine.upenn.edu
-
Hovedetterforsker:
- Joyce Wald, DO, FACC
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Har ikke rekruttert ennå
- Allegheny General Hospital
-
Hovedetterforsker:
- Matthew Lander, MD
-
Ta kontakt med:
- Laurie Machen
- Telefonnummer: 412-359-6181
- E-post: Laurie.Machen@ahn.org
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Har ikke rekruttert ennå
- UPMC Presbyterian
-
Ta kontakt med:
- Traci Mc Gaha
- Telefonnummer: 412-692-2769
- E-post: mcgahatl4@upmc.edu
-
Hovedetterforsker:
- Sideris Facaros, MD
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 32703
- Har ikke rekruttert ennå
- Centennial Medical Center
-
Ta kontakt med:
- Kristen Kuhn
- Telefonnummer: 615.982.0640
- E-post: kristen.kuhn2@hcahealthcare.com
-
Hovedetterforsker:
- Thomas McRae, MD, FACC
-
Hovedetterforsker:
- Zachary J II'Giovine, MD, FACC
-
-
Texas
-
Dallas, Texas, Forente stater, 75243
- Rekruttering
- Medical City Heart Hospital Dallas
-
Ta kontakt med:
- Lauren Horton
- Telefonnummer: 469-887-3274
- E-post: lauren.horton2@hcahealthcare.com
-
Hovedetterforsker:
- Song Li, MD
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- Har ikke rekruttert ennå
- University of Utah
-
Hovedetterforsker:
- Stavros Drakos, MD
-
Ta kontakt med:
- Ashley Elmer
- Telefonnummer: 801.585.6775
- E-post: ashley.elmer@hsc.utah.edu
-
Hovedetterforsker:
- Thomas Hanff, MD
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Har ikke rekruttert ennå
- Inova Fairfax Hospital
-
Hovedetterforsker:
- Shashank Sinha, MD
-
Ta kontakt med:
- Bhruga Shah
- Telefonnummer: 703-776-2828
- E-post: Bhruga.shah@inova.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Age ≥ 18 and < 80 years
-
Subject or subject's legally authorized representative (LAR) has signed the Informed Consent Form
-
LVEF ≤ 40%
-
Subject is presenting with decompensated heart failure and meets at least two (2) of the following cardiogenic shock criteria:
- Hypotension (sustained episode of systolic blood pressure ≤ 90 mmHg for at least 30 minutes or need for inotropic/vasoactive agents to maintain such blood pressure)
- Hypoperfusion (physical sign(s) of organ hypoperfusion or serum lactate >2 mmol/L)
- Cardiac index (CI) < 2.2 L/min/m2 determined to be secondary to cardiac dysfunction, in the absence of hypovolemia
- Required support with an intra-aortic balloon pump (IABP) or Impella CP™
-
Subject has inadequate heart failure GDMT based on the most recent outpatient prescription prior to index admission, defined as:
- On 2 or less of the 4-Pillar HF Drug Classes (BB, MRA, SGLT2i, and RASi)
- If on BB and RASi, at least one of the two medications is < 50% of the maximal target dose
Exclusion Criteria:
-
Underlying unmodifiable conditions that limit initiation of GDMT prior to enrollment, including but not limited to:
-
Drug allergies or hypersensitivities* to HF GDMT medications, unless alternative can be identified
*Drug allergy/hypersensitivity is an immune-mediated reaction to a medication. Adverse reactions must be a result of immune or inflammatory cell stimulations by the mеԁiсаtion.
-
Known bilateral renal artery stenosis
-
Type 1 diabetes
-
2o or 3o AV block, unless pacemaker is in place
-
Angioedema, hereditary or idiopathic
-
Pregnancy, known or confirmed by a pregnancy test if of childbearing potential
-
-
ST-segment elevation or acute coronary syndrome (ACS) prior to enrollment
-
Septic shock, shock from non-cardiac origins, or mixed shock
-
SCAI Stage E cardiogenic shock per study definition (Appendix C) prior to enrollment
-
In cardiac arrest prior to enrollment
-
Prolonged use (or use with complication) of Intra-aortic balloon pump (IABP) or Impella CP™ prior to enrollment, meeting at least one of the following:
- IABP use >24 hours if placed at the enrolling site or >48 hours if transferred on IABP
- Impella CP™ use >24 hours if placed at the enrolling site or >48 hours if transferred on Impella CP™
- Experienced complication(s) from IABP including clinically significant vascular injury, limb ischemia, end organ damage, or bleeding requiring transfusion(s) per Investigator's discretion
- Experienced complication(s) from Impella CP™ including clinically significant hemolysis, vascular injury, limb ischemia, end organ damage, or bleeding requiring transfusion(s) per Investigator's discretion
-
On mechanical circulatory support other than IABP or Impella CP™ (i.e. ECMO, etc) or on mechanical ventilation for non-procedural reasons prior to enrollment
-
Revascularization or cardiac surgery within 30-days prior to enrollment
-
Infiltrative/restrictive cardiomyopathy (sarcoidosis and amyloidosis), hypertrophic cardiomyopathy, constrictive pericarditis, pericardiac tamponade, or myocarditis requiring high-dose immunosuppression
-
Complex adult congenital heart disease
-
Primary severe valvular disease
-
Predominant RV dysfunction per Investigator's discretion
-
History of heart transplant or listed for heart transplant or planned for heart transplantation prior to enrollment
-
Planned to be implanted with a permanent VAD within 180-days of the index hospitalization date
-
Continuous outpatient inotropic support prior to the index hospitalization date
-
Planned to pursue palliative care or hospice, or life expectancy of less than 1 year due to non-cardiac illness at the time of index hospitalization date
-
Currently on dialysis, or has pre-existing end-stage chronic kidney disease (stage 4 and above), or has nephropathy of hereditary, infectious, or autoimmune origin
-
Pre-existing functional liver disease including liver cirrhosis, alcoholic hepatitis, metabolic dysfunction associated steatohepatitis (MASH), or genetic liver disease
-
Pre-existing pulmonary disease with oxygen dependency
-
History of stroke or intracranial hemorrhage ≤ 90 days prior to the index hospitalization date, or a history of cerebrovascular disease with significant (> 80%) uncorrected carotid stenosis, or any permanent neurological deficit with modified Rankin Scale (mRS) >2
-
Any contraindication that precludes placing an Impella 5.5™, including but not limited to:
- Aortic valve stenosis/calcification with orifice area ≤ 0.6cm2 or aortic insufficiency of any grade greater than mild on pre-procedure echocardiography
- Presence of mechanical aortic valve or heart constrictive device
- Mural thrombus in the left ventricle
- Severe arterial disease precluding placement of Impella
- Presence of atrial or ventricular septal defect
- Left ventricular rupture
- Cardiac tamponade
- Combined cardiorespiratory failure
-
Infection of the planned procedural access site or systemic active infection including sepsis and bacteremia
-
Intolerance to anticoagulant or antiplatelet therapies, or will refuse blood transfusions
-
Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures
-
Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device
-
Subject belongs to a vulnerable population, such as prisoners, pregnant women, handicapped, mentally disabled persons, or economically or educationally disadvantaged persons per 21CFR56.111(a)(3) and 111(b)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Single arm study
This is a single arm study. |
The intervention is Impella 5.5 with SmartAssist® support combined with protocolized guideline directed medical therapy (GDMT) and HF-CS best practices. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Sammensetning av død uansett årsak, HF-sykehusinnleggelse og hjerteerstatning (hjertetransplantasjon eller varig LVAD-implantasjon)
Tidsramme: Tidsramme: 180 dager etter inklusjon
|
Tidsramme: 180 dager etter inklusjon
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sammensatt av død uansett årsak og erstatning av hjerte
Tidsramme: 90 dager, 180 dager, 1 år etter inkludering
|
90 dager, 180 dager, 1 år etter inkludering
|
|
|
Sammensatt av død uansett årsak, HF-sykehusinnleggelse og hjerteerstatning
Tidsramme: 90 dager, 1 år etter registrering
|
90 dager, 1 år etter registrering
|
|
|
Dødelighet av alle årsaker
Tidsramme: Utskrivelse fra sykehus (innen 24 timer), 90 dager, 180 dager, 1 år etter påmelding
|
Utskrivelse fra sykehus (innen 24 timer), 90 dager, 180 dager, 1 år etter påmelding
|
|
|
Kardiovaskulær dødelighet
Tidsramme: Utskrivning fra sykehus (innen 24 timer), 90 dager, 180 dager, 1 år etter inklusjon
|
Utskrivning fra sykehus (innen 24 timer), 90 dager, 180 dager, 1 år etter inklusjon
|
|
|
Sammensatt av død uansett årsak og forverret hjertesvikt
Tidsramme: 90 dager, 180 dager, 1 år etter påmelding
|
90 dager, 180 dager, 1 år etter påmelding
|
|
|
Ikke-HF kardiovaskulær sykehusinnleggelse
Tidsramme: 90 dager, 180 dager, 1 år etter inkludering
|
90 dager, 180 dager, 1 år etter inkludering
|
|
|
Alle kardiovaskulære sykehusinnleggelser
Tidsramme: 90 dager, 180 dager, 1 år etter innmelding
|
90 dager, 180 dager, 1 år etter innmelding
|
|
|
Sammensetning av dødsfall uansett årsak og enhver kardiovaskulær sykehusinnleggelse
Tidsramme: 90 dager, 180 dager, 1 år etter inkludering
|
90 dager, 180 dager, 1 år etter inkludering
|
|
|
Change in LVEF from baseline
Tidsramme: 180 dager etter utskrivelse
|
180 dager etter utskrivelse
|
|
|
Endring i LVEDD fra baseline
Tidsramme: 180 dager etter utskrivelse
|
180 dager etter utskrivelse
|
|
|
Endring i NYHA HF-klasse fra baseline
Tidsramme: 180 dager etter utskrivelse
|
180 dager etter utskrivelse
|
|
|
Worsening heart failure
Tidsramme: 90-days, 180-days, 1-year post-enrollment
|
HF hospitalization or urgent HF visit |
90-days, 180-days, 1-year post-enrollment
|
|
Rate of major device-related adverse events
Tidsramme: Hospital Discharge (within 24 hours), 30-days post-enrollment
|
The composite rate of any of the following device-related serious adverse events:
|
Hospital Discharge (within 24 hours), 30-days post-enrollment
|
|
Subjects achieving indicated GDMT treatment
Tidsramme: Hospital Discharge(within 24 hours), 90-days, 180-days post-enrollment
|
Achieving any dose of all four classes |
Hospital Discharge(within 24 hours), 90-days, 180-days post-enrollment
|
|
% of Subjects achieving optimized GDMT treatment
Tidsramme: 90-days and 180-days post-enrollment
|
Achieving at least 50% of the target dose of all four classes |
90-days and 180-days post-enrollment
|
|
Modified Heart Failure Collaboratory (mHFC) score
Tidsramme: Hospital Discharge(within 24 hours), 90-days, 180-days post-enrollment
|
Defined by HFC in 2022. Improvement from baseline |
Hospital Discharge(within 24 hours), 90-days, 180-days post-enrollment
|
|
Rate of GDMT-Related Serious Adverse Events
Tidsramme: Hospital Discharge (within 24 hours), 90-days, and 180-days post-enrollment
|
The composite rate of any of the following GDMT-related serious adverse events:
|
Hospital Discharge (within 24 hours), 90-days, and 180-days post-enrollment
|
|
Quality of life assessed by EQ-5D
Tidsramme: 180-days and 1-year post-discharge
|
improvement from baseline |
180-days and 1-year post-discharge
|
|
6-Minute Walk Test Distance
Tidsramme: 180-days and 1-year post-discharge
|
improvement from baseline |
180-days and 1-year post-discharge
|
|
Change in HF biomarker
Tidsramme: Hospital Discharge (within 24 hours), 30-days, and 90-days post-discharge
|
NT-proBNP from baseline |
Hospital Discharge (within 24 hours), 30-days, and 90-days post-discharge
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Adam DeVore, MD, MHS, Duke University
- Hovedetterforsker: Gavin Hickey, MD, University of Pittsburgh
- Hovedetterforsker: Manreet Kanwar, MD, University of Chicago
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- INTeGRATE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .